1160246-91-2

Usage

Uses

Used in Pharmaceutical Research:
TBOA-8 is utilized as a research compound for studying the role of glutamate transporters in neurological processes. Its function as a competitive antagonist allows scientists to investigate the effects of modulating glutamate transporter activity on various conditions related to neurotransmission.
Used in Neurological Disorders Treatment:
In the field of neurology, TBOA-8 is considered for potential use as a therapeutic agent in the treatment of neurological disorders associated with imbalances in glutamate levels, such as neurodegenerative diseases and excitotoxicity conditions. Its ability to modulate glutamate transporter activity could provide a means to regulate excitatory neurotransmission, thereby offering a novel approach to managing these disorders.
Used in Drug Development:
TBOA-8 serves as a lead compound in drug development efforts focused on designing new medications targeting glutamate transporters. Its unique spirocyclic structure provides a foundation for chemical modifications aimed at enhancing its potency, selectivity, and pharmacokinetic properties, with the goal of creating more effective and safer drugs for treating related neurological conditions.
Used in Neurotransmission Studies:
In academic and research settings, TBOA-8 is employed as a tool to probe the mechanisms of neurotransmitter transport and signaling. Its interaction with glutamate transporters helps researchers understand the intricate processes of neuronal communication and how disruptions in these processes can lead to various neurological and neuropsychiatric diseases.

Upstream product

• 954236-44-3 tert-butyl 3-oxo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate 
• 203662-51-5 1-(t-butoxycarbonyl)-4-(prop-2-enyl)-4-hydroxypiperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 898157-46-5 tert-butyl 3-bromo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate 

Relevant academic research and scientific papers

Application of Flow and Biocatalytic Transaminase Technology for the Synthesis of a 1-Oxa-8-azaspiro[4.5]decan-3-amine

Spirocyclic ring systems are useful intermediates in the design and synthesis of medicinally active agents and commonly found as cores in natural products. Recently, syntheses of a key intermediate Boc-protected-1-oxa-8-azaspiro[4.5]decan-3-amine 1 were examined. While multigram quantities of the racemic material could be made from the reduction of an energic azide intermediate, larger scale reactions and a chiral synthesis required further investigations. Herein, we describe the use of a continuous three-step flow process to scale the formation and reduction of an azide intermediate, and the use of a transaminase to prepare the desired enantiomer in high yield and enantiomeric excess.

HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS

The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or sa

1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS

The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses